Neuroprotective effect of topiramate on focal ischemic brain damage in rats

沈沸,苗玲,徐群,张毅
DOI: https://doi.org/10.3321/j.issn:1673-8225.2004.13.052
2004-01-01
Abstract:BACKGROUND: Recent studies have found that topiramate(TPM) is capable of suppressing voltage-gated Na+channel, enhancing γ-aminobutyric acid(GABA) activity, and inhibiting α- amino- 3-hydroxy - 5- methylisoxazole-4-propionic acid(AMPA)/kainate (KA) type glutamic acid receptor-mediated effects, thereby deducing that it possesses neuroprotective activity.OBJECTIVE: To investigate the neuroprotective effects of TPM against focal ischemic brain damage in rats.DESIGN: Completely randomized controlled trial.SETTING and MATERIALS: This study was conducted in the Neurobiological Laboratory of Renji Hospital affiliated to Shanghai Second Medical University. Fifty healthy male SD rats weighing 280 -350 g were purchased from Shanghai Experimental Animal Center of Chinese Academy of Science.INTERVENTION: Focal brain isehemic models were successfully established in 50 SD rats by intravascular occlusion of the middle cerebral artery with nylon suture, and then randomly divided into control group( n = 10)and two TPM treatment groups( n = 20 in both groups). Thirty minutes after group) or TPM(in the treatment groups at the dose of 40 and 80 mg/kg,respectively).MAIN OUTCOME MEASURES: The neurological deficits were scored 4and 24 hours following the ischemia respectively. The cerebral water content was measured 24 hours after ischemia, and the infarction volume was determined by using 2, 3, 5- triphenyltetrazolium chloride(TTC) staining.TPM groups measured at 24 hours following the ischemia(3.20 ±0.52 and 2.70 ± 0.47, respectively) were significantly different from those at 4 hours after ischemia(3.90 ± 0.31 and 3.80 ± 0. 41; P < 0. 01 ), and the scores at 24 hours were significantly lower than that of the control group(3.80 ±affected hemisphere in 40 and 80 mg/kg TPM treatment groups were (81.98 ±0. 78)% and(80. 38 ±0.80)% respectively, significantly lower than that of the control group[ (83.05 ±0.56)%; P < 0.05 and P <that in the control group[(41.40 ± 3.36)% ], was reduced to(38.00 ±4. 26)% in 40 mg/kg TPM group( P = 0. 168 6), and to(34. 50 ± 6.52)%in 80 mg/kg TPM group( P < 0. 05).CONCLUSION: TPM produces neuroprotective effects to alleviate neurological deficits, reduce cerebral edema, and even decrease infarct volume dose-dependently in rat models of focal ischemic brain damage.
What problem does this paper attempt to address?